- call +1-201-465-4211
- email sales@mrinsights.biz
Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time.
Scope of the Report:
This report studies the Chronic Obstructive Pulmonary Disorder market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Chronic Obstructive Pulmonary Disorder market by product type and applications/end industries.
The growth of the global chronic obstructive pulmonary disease (COPD) market is expected to be fueled by a high number of new, more efficacious and convenient products entering the market and commanding a greater value compared to the therapies already existing in the market. Another major factor propelling the growth of the market is the introduction of novel innovations like ultrasonic nebulizers, which are superior to the existing jet nebulizers. The competitive environment is expected to intensify with an increase in product extensions, technological innovations, and an increase in the number of mergers and acquisitions. The market for COPD drugs shows potential opportunity in both developed and developing countries. Due to the effectiveness and advancements in technology, many companies are focusing and collaborating to develop innovative COPD drugs and treatments.
The global Chronic Obstructive Pulmonary Disorder market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Chronic Obstructive Pulmonary Disorder.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
GSK
Pfizer
Merck
Novartis
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceuticals
Ario Pharma
Roche
Ache
Almirall
Aquinox Pharmaceuticals
Asmacure
Astellas Pharma
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Short-Acting Bronchodilators
Corticosteroids
Methylxanthines
Long-Acting Bronchodilators
Phosphodiesterase-4 Inhibitors
Others
Market Segment by Applications, can be divided into
Hospitals
Clinics
Others
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Chronic Obstructive Pulmonary Disorder Market Overview
1.1 Product Overview and Scope of Chronic Obstructive Pulmonary Disorder
1.2 Classification of Chronic Obstructive Pulmonary Disorder by Types
1.2.1 Global Chronic Obstructive Pulmonary Disorder Revenue Comparison by Types (2017-2023)
1.2.2 Global Chronic Obstructive Pulmonary Disorder Revenue Market Share by Types in 2017
1.2.3 Short-Acting Bronchodilators
1.2.4 Corticosteroids
1.2.5 Methylxanthines
1.2.6 Long-Acting Bronchodilators
1.2.7 Phosphodiesterase-4 Inhibitors
1.2.8 Others
1.3 Global Chronic Obstructive Pulmonary Disorder Market by Application
1.3.1 Global Chronic Obstructive Pulmonary Disorder Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Chronic Obstructive Pulmonary Disorder Market by Regions
1.4.1 Global Chronic Obstructive Pulmonary Disorder Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Chronic Obstructive Pulmonary Disorder Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Chronic Obstructive Pulmonary Disorder Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Chronic Obstructive Pulmonary Disorder Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Chronic Obstructive Pulmonary Disorder Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Chronic Obstructive Pulmonary Disorder Status and Prospect (2013-2023)
1.5 Global Market Size of Chronic Obstructive Pulmonary Disorder (2013-2023)
2 Manufacturers Profiles
2.1 GSK
2.1.1 Business Overview
2.1.2 Chronic Obstructive Pulmonary Disorder Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 GSK Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2016-2017)
2.2 Pfizer
2.2.1 Business Overview
2.2.2 Chronic Obstructive Pulmonary Disorder Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Pfizer Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2016-2017)
2.3 Merck
2.3.1 Business Overview
2.3.2 Chronic Obstructive Pulmonary Disorder Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Merck Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2016-2017)
2.4 Novartis
2.4.1 Business Overview
2.4.2 Chronic Obstructive Pulmonary Disorder Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Novartis Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2016-2017)
2.5 AstraZeneca
2.5.1 Business Overview
2.5.2 Chronic Obstructive Pulmonary Disorder Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 AstraZeneca Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2016-2017)
2.6 Boehringer Ingelheim
2.6.1 Business Overview
2.6.2 Chronic Obstructive Pulmonary Disorder Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2016-2017)
2.7 Teva Pharmaceuticals
2.7.1 Business Overview
2.7.2 Chronic Obstructive Pulmonary Disorder Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2016-2017)
2.8 Ario Pharma
2.8.1 Business Overview
2.8.2 Chronic Obstructive Pulmonary Disorder Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Ario Pharma Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2016-2017)
2.9 Roche
2.9.1 Business Overview
2.9.2 Chronic Obstructive Pulmonary Disorder Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Roche Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2016-2017)
2.10 Ache
2.10.1 Business Overview
2.10.2 Chronic Obstructive Pulmonary Disorder Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Ache Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2016-2017)
2.11 Almirall
2.11.1 Business Overview
2.11.2 Chronic Obstructive Pulmonary Disorder Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Almirall Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2016-2017)
2.12 Aquinox Pharmaceuticals
2.12.1 Business Overview
2.12.2 Chronic Obstructive Pulmonary Disorder Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2016-2017)
2.13 Asmacure
2.13.1 Business Overview
2.13.2 Chronic Obstructive Pulmonary Disorder Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Asmacure Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2016-2017)
2.14 Astellas Pharma
2.14.1 Business Overview
2.14.2 Chronic Obstructive Pulmonary Disorder Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Astellas Pharma Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2016-2017)
3 Global Chronic Obstructive Pulmonary Disorder Market Competition, by Players
3.1 Global Chronic Obstructive Pulmonary Disorder Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Chronic Obstructive Pulmonary Disorder Players Market Share
3.2.2 Top 10 Chronic Obstructive Pulmonary Disorder Players Market Share
3.3 Market Competition Trend
4 Global Chronic Obstructive Pulmonary Disorder Market Size by Regions
4.1 Global Chronic Obstructive Pulmonary Disorder Revenue and Market Share by Regions
4.2 North America Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
4.3 Europe Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
4.5 South America Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
5 North America Chronic Obstructive Pulmonary Disorder Revenue by Countries
5.1 North America Chronic Obstructive Pulmonary Disorder Revenue by Countries (2013-2018)
5.2 USA Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
5.3 Canada Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
5.4 Mexico Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
6 Europe Chronic Obstructive Pulmonary Disorder Revenue by Countries
6.1 Europe Chronic Obstructive Pulmonary Disorder Revenue by Countries (2013-2018)
6.2 Germany Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
6.3 UK Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
6.4 France Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
6.5 Russia Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
6.6 Italy Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Chronic Obstructive Pulmonary Disorder Revenue by Countries
7.1 Asia-Pacific Chronic Obstructive Pulmonary Disorder Revenue by Countries (2013-2018)
7.2 China Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
7.3 Japan Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
7.4 Korea Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
7.5 India Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
8 South America Chronic Obstructive Pulmonary Disorder Revenue by Countries
8.1 South America Chronic Obstructive Pulmonary Disorder Revenue by Countries (2013-2018)
8.2 Brazil Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
8.3 Argentina Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
8.4 Colombia Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Chronic Obstructive Pulmonary Disorder by Countries
9.1 Middle East and Africa Chronic Obstructive Pulmonary Disorder Revenue by Countries (2013-2018)
9.2 Saudi Arabia Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
9.3 UAE Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
9.4 Egypt Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
9.5 Nigeria Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
9.6 South Africa Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2013-2018)
10 Global Chronic Obstructive Pulmonary Disorder Market Segment by Type
10.1 Global Chronic Obstructive Pulmonary Disorder Revenue and Market Share by Type (2013-2018)
10.2 Global Chronic Obstructive Pulmonary Disorder Market Forecast by Type (2018-2023)
10.3 Short-Acting Bronchodilators Revenue Growth Rate (2013-2023)
10.4 Corticosteroids Revenue Growth Rate (2013-2023)
10.5 Methylxanthines Revenue Growth Rate (2013-2023)
10.6 Long-Acting Bronchodilators Revenue Growth Rate (2013-2023)
10.7 Phosphodiesterase-4 Inhibitors Revenue Growth Rate (2013-2023)
10.8 Others Revenue Growth Rate (2013-2023)
11 Global Chronic Obstructive Pulmonary Disorder Market Segment by Application
11.1 Global Chronic Obstructive Pulmonary Disorder Revenue Market Share by Application (2013-2018)
11.2 Chronic Obstructive Pulmonary Disorder Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Clinics Revenue Growth (2013-2018)
11.5 Others Revenue Growth (2013-2018)
12 Global Chronic Obstructive Pulmonary Disorder Market Size Forecast (2018-2023)
12.1 Global Chronic Obstructive Pulmonary Disorder Market Size Forecast (2018-2023)
12.2 Global Chronic Obstructive Pulmonary Disorder Market Forecast by Regions (2018-2023)
12.3 North America Chronic Obstructive Pulmonary Disorder Revenue Market Forecast (2018-2023)
12.4 Europe Chronic Obstructive Pulmonary Disorder Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Chronic Obstructive Pulmonary Disorder Revenue Market Forecast (2018-2023)
12.6 South America Chronic Obstructive Pulmonary Disorder Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Chronic Obstructive Pulmonary Disorder Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Chronic Obstructive Pulmonary Disorder Picture
Table Product Specifications of Chronic Obstructive Pulmonary Disorder
Table Global Chronic Obstructive Pulmonary Diso
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
